Literature DB >> 16046885

Chemotherapy-induced nausea/vomiting and functional status in women treated for breast cancer.

Jiyeon Lee1, Suzanne L Dibble, Mary Pickett, Judith Luce.   

Abstract

Nausea and vomiting are among the most distressing symptoms for cancer patients treated with chemotherapy even with the widespread use of 5-HT3 antagonists. Chemotherapy-induced nausea and vomiting (CINV) is composed of 4 major components: acute nausea, delayed nausea, acute vomiting, and delayed vomiting. Determining the relationship of each component of CINV on the functional status of women undergoing chemotherapy for breast cancer was the purpose of this study. This longitudinal, descriptive study recruited 303 patients with breast cancer undergoing chemotherapy from 40 study sites in the United States. Reliable and valid measures of CINV and functional status were employed. Patients demonstrated significant decreases in the following aspects of functional status as measured by the SF-36: physical functioning (P < .0005), role limitations due to physical problems (P = .003), general health (P = .029), vitality (P < .0005), and social functioning (P = .001). The pattern of reduction in usual activities and increase in hours of resting correlated best with 2 components of CINV--delayed nausea and delayed vomiting (P < .0001, each). The results of this study suggest that control of delayed CINV may contribute to the functional improvement of women receiving chemotherapy for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046885     DOI: 10.1097/00002820-200507000-00002

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  8 in total

1.  The Effects of Symptoms on Quality of Life during Chemotherapy in African-American Women with Breast Cancer.

Authors:  Fannie Gaton-Johansson; Crystal C Watkins; Iye Kamara Kanu; Erin Whitehouse; Elisabeth Kenne Sarenmalm; Maria Brovall; Sharon L Kozachik
Journal:  J Natl Black Nurses Assoc       Date:  2015-12

2.  Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

Authors:  Sun Young Rha; Yeonhee Park; Su Kyung Song; Chung Eun Lee; Jiyeon Lee
Journal:  Support Care Cancer       Date:  2016-03-16       Impact factor: 3.603

3.  Feasibility study of a randomized controlled trial of a telephone-delivered problem-solving-occupational therapy intervention to reduce participation restrictions in rural breast cancer survivors undergoing chemotherapy.

Authors:  Mark T Hegel; Kathleen D Lyons; Jay G Hull; Peter Kaufman; Laura Urquhart; Zhongze Li; Tim A Ahles
Journal:  Psychooncology       Date:  2010-09-05       Impact factor: 3.894

4.  Distinct Trajectories of Fatigue and Sleep Disturbance in Women Receiving Chemotherapy for Breast Cancer.

Authors:  Meagan Whisenant; Bob Wong; Sandra A Mitchell; Susan L Beck; Kathi Mooney
Journal:  Oncol Nurs Forum       Date:  2017-11-01       Impact factor: 2.172

5.  The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting.

Authors:  G Dranitsaris; A Molassiotis; M Clemons; E Roeland; L Schwartzberg; P Dielenseger; K Jordan; A Young; M Aapro
Journal:  Ann Oncol       Date:  2017-06-01       Impact factor: 32.976

6.  Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting.

Authors:  Prasan R Bhandari
Journal:  J Adv Pharm Technol Res       Date:  2012-10

7.  A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.

Authors:  Mark A Ware; Paul Daeninck; Vincent Maida
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

8.  Guided Imagery And Progressive Muscle Relaxation as a Cluster of Symptoms Management Intervention in Patients Receiving Chemotherapy: A Randomized Control Trial.

Authors:  Andreas Charalambous; Margarita Giannakopoulou; Evaggelos Bozas; Yiola Marcou; Petros Kitsios; Lefkios Paikousis
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.